Put Options

2 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$392.81 - $485.53 $174,800 - $216,060
445 New
445 $209 Million
Q4 2023

Feb 06, 2024

BUY
$343.0 - $410.68 $190,365 - $227,927
555 New
555 $226 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $119B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Genus Capital Management Inc. Portfolio

Follow Genus Capital Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Genus Capital Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Genus Capital Management Inc. with notifications on news.